Literature DB >> 11340621

Hypocretin/orexin, sleep and narcolepsy.

M Hungs1, E Mignot.   

Abstract

The discovery that hypocretins are involved in narcolepsy, a disorder associated with excessive daytime sleepiness, cataplexy and unusually rapid transitions to rapid-eye-movement sleep, opens a new field of investigation in the area of sleep control physiology. Hypocretin-1 and -2 (also called orexin-A and -B) are newly discovered neuropeptides processed from a common precursor, preprohypocretin. Hypocretin-containing cells are located exclusively in the lateral hypothalamus, with widespread projections to the entire neuroaxis. Two known receptors, Hcrtr1 and Hcrtr2, have been reported. The functional significance of the hypocretin system is rapidly emerging in both animals and humans. Hypocretin abnormalities cause narcolepsy in dogs, human and mice. The role of the hypocretin system in normal sleep regulation is more uncertain. We believe hypocretin cells drive cholinergic and monoaminergic activity across the sleep cycle. Input from the suprachiasmatic nucleus to hypocretin-containing neurons may explain the occurrence of clock-dependent alertness. Other functions are suggested by pharmacological and neurochemical experiments. These include regulation of food intake, neuroendocrine function, autonomic nervous system activity and energy balance. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340621     DOI: 10.1002/bies.1058

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  32 in total

Review 1.  Psychogenomics: opportunities for understanding addiction.

Authors:  E J Nestler
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

2.  Release of hypocretin (orexin) during waking and sleep states.

Authors:  Lyudmila I Kiyashchenko; Boris Y Mileykovskiy; Nigel Maidment; Hoa A Lam; Ming-Fung Wu; Joshi John; John Peever; Jerome M Siegel
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

3.  [The neurotransmitter, hypocretin. An overview].

Authors:  C Baumann; C Bassetti
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

Review 4.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

5.  The sleep-feeding conflict: Understanding behavioral integration through genetic analysis in Drosophila.

Authors:  Daniel M McDonald; Alex C Keene
Journal:  Aging (Albany NY)       Date:  2010-08       Impact factor: 5.682

Review 6.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

Review 7.  Animal models of sleep disorders.

Authors:  Linda A Toth; Pavan Bhargava
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

8.  [Relationships between sleep and addiction].

Authors:  Francesca Cañellas; Luis de Lecea
Journal:  Adicciones       Date:  2012       Impact factor: 2.979

9.  Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons.

Authors:  Laurence Bayer; Emmanuel Eggermann; Benoît Saint-Mleux; Danièle Machard; Barbara E Jones; Michel Mühlethaler; Mauro Serafin
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

10.  Predicting Risk in Space: Genetic Markers for Differential Vulnerability to Sleep Restriction.

Authors:  Namni Goel; David F Dinges
Journal:  Acta Astronaut       Date:  2012-08       Impact factor: 2.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.